长春高新(000661.SZ)：注射用GenSci139境内生产药品临床试验获批

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the approval from the National Medical Products Administration for the clinical trial of GenSci139 injection in patients with advanced solid tumors [1] Group 1 - The approval allows Jinsai Pharmaceutical to conduct clinical trials for GenSci139, indicating progress in the company's drug development pipeline [1] - This development may enhance the company's position in the oncology market, potentially leading to new treatment options for patients with advanced solid tumors [1]